Israel Active

I reported previously () on the minimally-invasive inter-uterine device from Israel’s POP Medical that repairs Pelvic Organ Prolapse (POP) affecting 50% of women. The FDA-approved NeuGuide is soon to undergo new trials in the US and Israel to build confidence and data.

Tel Aviv University is establishing an innovation center for translational medicine. The aim is to reduce the time for bringing a new treatment to market by combining academic research with clinical trials.  Only afterwards will the treatment be licensed to a commercial company.

In December, Israel’s Technion hosted the first international conference on biomedical informatics – where data collected by universities, hospitals and health funds is analyzed and the results used to adapt treatments to individual patients.

Israel’s BioLineRx has announced encouraging initial results from its Phase 2a trials of its BL-8040 treatment on patients with metastatic pancreatic cancer. After only five days of treatment the treatment substantially increased the numbers of T-cells fighting the tumors.

In Davos, Israeli PM Netanyahu met with William McDermott, the CEO of SAP who agreed to partner with Israel on a new five-year NIS 1 billion digital healthcare project. The project aims to develop personalized and preventative medicine – regarded as a revolution in the health sector.

Israel-based startup Montfort Brain Monitor won Israel’s Henry Ford Health System's artificial intelligence challenge. Montfort’s "master app" uses a smartphone's sensors to track a patient's motor, cognitive, and affective activity. It can be tailored for the specific neurological disorder.

Israel’s VBL Therapeutics has opened its new gene therapy production facility to manufacture VBL’s lead cancer therapy ofranergene obadenovec (VB-111), when finally approved. The Modiin gene therapy plant is one of the largest in the world, and the first in Israel.

This video shows that Israeli doctors are saving lives of cancer patients by testing different treatments on samples of the tumors outside of the patient’s body. They can then determine the best cancer treatments to offer patients based on the success of the treatment.

Viz.ai has received the CE Mark for its Israeli-developed Direct-to-Intervention system, ContaCT, a novel approach to stroke care that automatically analyzes brain CT-scans and notifies a specialist that a suspected large vessel occlusion has been identified.

Israel’s NRGene has confirmed the identity of a genetic mutation that causes colon cancer in 60% of its hosts. NRGene was contacted by scientists at Stanford University and used its GenoMagic software to genetically screen the DNA of inherited colon cancer sufferers.